PMID- 24087882
OWN - NLM
STAT- MEDLINE
DCOM- 20140512
LR  - 20161125
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 14
IP  - 16
DP  - 2013 Nov
TI  - Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes 
      mellitus.
PG  - 2281-96
LID - 10.1517/14656566.2013.838559 [doi]
AB  - INTRODUCTION: The global prevalence of type 2 diabetes mellitus (T2DM) is rapidly 
      increasing and is associated with a high risk of microvascular and macrovascular 
      complications. Although some glucose-lowering therapies are associated with 
      hypoglycemia and weight gain, glucagon-like peptide-1 (GLP-1) receptor agonists 
      represent a significant advance in the treatment of T2DM, as they provide 
      effective glycemic control with a low incidence of hypoglycemia and a beneficial 
      effect on body weight, as well as potential improvements in cardiovascular 
      outcomes. AREAS COVERED: This article evaluates the pharmacological and clinical 
      profile of the once-daily prandial GLP-1 receptor agonist lixisenatide for the 
      treatment of T2DM. EXPERT OPINION: Once-daily prandial lixisenatide has been 
      evaluated in an extensive clinical trials program, in which it was shown to have 
      a favorable safety and tolerability profile, and to effectively improve metabolic 
      control. The unique pharmacological properties of lixisenatide clearly 
      differentiate it from other GLP-1 receptor agonists. As a once-daily agonist with 
      a high affinity for the GLP-1 receptor, lixisenatide improves overall glycemic 
      control, with particularly strong effects on postprandial plasma glucose levels. 
      These attributes encourage the application of lixisenatide in those patients with 
      extensive postprandial glucose excursions, or in combination with other 
      antidiabetic drugs that have prevailing effects on fasting glucose levels.
FAU - Forst, Thomas
AU  - Forst T
AD  - Profil Mainz , Hellersbergstrasse 9, D-41460 Neuss , Germany +49 6131 5763613 ; 
      +49 6131 5763611 ; thomas.forst@profil.com.
FAU - Pfutzner, Andreas
AU  - Pfutzner A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20131003
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Glucagon)
RN  - 74O62BB01U (lixisenatide)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Peptides/pharmacology/*therapeutic use
MH  - Receptors, Glucagon/agonists
MH  - Treatment Outcome
EDAT- 2013/10/04 06:00
MHDA- 2014/05/13 06:00
CRDT- 2013/10/04 06:00
PHST- 2013/10/04 06:00 [entrez]
PHST- 2013/10/04 06:00 [pubmed]
PHST- 2014/05/13 06:00 [medline]
AID - 10.1517/14656566.2013.838559 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2013 Nov;14(16):2281-96. doi: 
      10.1517/14656566.2013.838559. Epub 2013 Oct 3.